Highlights
- •Patients treated for differentiated thyroid cancer with different activities.
- •Significant differences in the biokinetics.
- •Correlation between the time-integrated activity and the remnant uptake.
Abstract
Purpose
To study the dependency of the effective half-life on the administered activity and
the correlation between the time-integrated activity and the remnant uptake at 2d
and 7d in patients treated for DTC with 1.11 GBq, 3.7 GBq or 5.55 GBq of 131I-NaI.
Methods
Ninety-two patients undergoing total thyroidectomy and lymph node removal were included.
If cancer had not spread to lymph nodes, patients received 1.11 GBq of 131I-NaI when the lesion maximal diameter was smaller than 4 cm, and 3.7 GBq for bigger
sizes. If cancer had spread to lymph nodes patients received 5.55 GBq. There were
30, 49 and 13 patients respectively treated with 1.11 GBq(Group 1), 3.7 GBq(Group
2) and 5.55 GBq(Group 3). Two SPECT/CT scans were performed at 2d and 7d after radioiodine
administration for each patient to determine the thyroid remnant activities and effective
half-lives of the radioiodine.
Results
Statistical analysis showed significant differences (p < 0.05) in the effective half-life among patients treated with 1.11 GBq, 3.7 GBq
and 5.55 GBq. A high positive correlation (ρ > 0.95) was found between the time-integrated
activity and the remnant activity at 2d for the three groups of patients.
Conclusions
There were significant differences in the effective half-life of the radioiodine in
remnants of patients treated with activities of 1.11 GBq, 3.7 GBq or 5.55 GBq. The
high positive linear correlation found between the time-integrated activity and the
remnant activity at 2d for the three groups of patients indicate that the time-integrated
activity could be estimated from one time-point.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Physica Medica: European Journal of Medical PhysicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.J Nucl Med. 2012; 53: 1633-1651
- Guidelines for radioiodine therapy of differentiated thyroid cancer.Eur J Nucl Med Mol Imaging. 2008; 35: 1941-1959
- Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.Eur J Nucl Med Mol Imaging. 2017; 44: 918-925
- Management of Thyroid Cancer and Related Nodular Disease.Springer-Verlag, London2006
- To treat or not to treat: The role of adjuvant radioiodine therapy in thyroid cancer patients.J Oncol. 2012; 2012: 1-11
- Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.N Engl J Med. 1983; 309: 937-941
- Iodine-131 treatment of thyroid cancer: Absorbed dose calculated from posttherapy scans.J Nucl Med. 1986; 1207–1211
- Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.Radiother Oncol. 1993; 28: 16-26
- Radioiodine therapy for welldifferentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery.J Nucl Med. 1994; 1944–1950
- Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.J Nucl Med. 2004; 45: 619-625
- A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.Eur J Nucl Med Mol Imaging. 2010; 37: 270-275
- Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer.Med Phys. 2016; 43: 5279-5287
- Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.J Nucl Med. 2016; 57: 1027-1032
- 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy.J Nucl Med. 2012; 53: 1310-1325
- Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131 I-NaI respectively.Phys Med. 2019; 65: 143-149
- Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism.Cancer Biother Radiopharm. 2003; 18: 473-479
- Thyroid Stunning: Fact or Fiction?.Semin Nucl Med. 2011; 41: 105-112
- Radioiodine Uptake in Thyroid Remnants During Therapy After Tracer Dosimetry.J Nucl Med. 2000; 41: 1082-1085
- The So-Called Stunning of Thyroid.J Nucl Med. 2006; 47: 1406-1412
Sobin LH, GospodarowiczMK, Wittekind C. TNM classification of malignant tumors. Wiley-Blackwell. New York; 2009.
International Atomic Energy Agency. Release of patients after radionuclide therapy. Safety Report Series No. 63, IAEA. Vienna; 2009.
Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2016.
- Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.J Nucl Med. 2008; 49: 1017-1023
- 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis.Thyroid. 2016; 26: 441-448
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL http://www.R-project.org/. 2020.
- Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal.J Nucl Med. 2006; 47: 648-654
- Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.Eur J Nucl Med Mol Imaging. 2017; 44: 935-940
- Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid Stunning.Cancer Res. 2007; 67: 7512-7517
- Statistical and radiobiological analysis of the so-called thyroid stunning.EJNMMI Research. 2015; 5: 67
- Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.Eur J Nucl Med. 2002; 29: 783-788
Kobe C, Eschner W, Wild M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun 2010; 31:201-5.
- Prediction of thyroidal 131I effective half-life in patients with Graves' disease.Oncotarget. 2017; 8: 80934-80940
Article info
Publication history
Published online: June 24, 2021
Accepted:
June 13,
2021
Received in revised form:
May 15,
2021
Received:
March 1,
2021
Identification
Copyright
© 2021 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
